退伍军人间歇性跛行患者下肢旁路术前的最佳内科管理
该研究基于2005至2015年全美退伍军人事务部外科质量改进项目数据库,回顾分析因间歇性跛行行择期下肢开放旁路术的患者,仅26%在术前12个月内达到最佳内科管理(OMM),且OMM与术后并发症、无截肢生存率及死亡率无显著差异。
要点
- 在10271例下肢旁路术中,2265例(22%)为间歇性跛行患者,仅581例(26%)术前达到OMM。
- OMM各组分依从性不一:抗血小板55%、他汀63%、戒烟58%、糖化血红蛋白监测92%。
- 风险校正后,OMM组与非OMM组的并发症率、无截肢生存率及死亡率均无统计学显著差异。
核心结论
- 仅约四分之一退伍军人间歇性跛行患者在开放下肢旁路术前一年内被记录接受OMM,提示需加强术前内科治疗。
- 但术前OMM记录并未改善短期或长期术后结局,提示需要更客观的内科管理指标以确保外周动脉疾病目标达成。
研究设计与样本
- 回顾性队列研究,数据来自退伍军人事务部外科质量改进项目数据库,纳入2005年至2015年全美退伍军人医疗中心因间歇性跛行行择期开放下肢旁路术的患者。
- OMM定义为术前12个月内记录具备以下全部:抗血小板药、他汀、戒烟治疗(若吸烟)及糖化血红蛋白监测(若糖尿病)。
- 采用多变量回归和Cox比例风险模型并结合逆概率治疗加权分析OMM对结局的影响,校正患者层面混杂因素。
主要发现
- 共10271例下肢旁路术,其中2265例(22%)为间歇性跛行患者,中位年龄63岁(四分位距58-68岁)。
- 839例(37%)为糖尿病患者,1333例(59%)在术前12个月内吸烟。
- 仅581例(26%)术前达到OMM;组分依从性:抗血小板55%、他汀63%、戒烟58%、糖化血红蛋白监测92%。
- 风险校正分析显示,OMM组与非OMM组在并发症率、无截肢生存率及死亡率方面均无统计学显著差异。
临床怎么用
- 作者认为需要策略确保在外科血运重建前强化内科治疗。
- 作者认为需要更客观的内科管理指标以确保外周动脉疾病目标达成。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Optimizing medical management through glucose control, smoking cessation, and drug therapy (ie, antiplatelet and statin agents) is recommended as first-line therapy for patients with claudication. The aims of this study were to determine how frequently veterans with claudication received optimal medical management (OMM) before undergoing elective open lower extremity bypass procedures nationwide and whether preoperative OMM was associated with improved surgical outcomes. METHODS: We reviewed all patients within the Veterans Affairs (VA) Surgical Quality Improvement Program database who underwent elective open lower extremity bypass procedures for claudication at nationwide VA medical centers from 2005 until 2015. We defined OMM as a claudicant's having documentation of receiving all of the following within 12 months before surgery: prescriptions for antiplatelet, statin, and smoking cessation therapy (if a smoker) and monitoring of hemoglobin A1c (if diabetic). Outcome measures included occurrence of any 30-day VA Surgical Quality Improvement Program complication, amputation-free survival, and 30-day and 1-year mortality. We used multivariate regression and Cox proportional hazards models incorporating inverse probability treatment weighting to analyze the effect of OMM on outcome measures after adjusting for patient-level confounding. RESULTS: Among 10,271 lower extremity bypass procedures performed, 2265 (22%) were undertaken in claudicants with a median age of 63 years (interquartile range, 58-68 years). Of claudicants, 839 (37%) were diabetic, and 1333 (59%) patients smoked within 12 months before surgery. OMM was achieved in only 581 (26%) claudicants before they underwent surgery, although adherence to individual components was variable: antiplatelet, 55%; statin, 63%; smoking cessation, 58%; and hemoglobin A1c monitoring, 92%. In risk-adjusted analyses, there were no statistically significant differences in complication rates, amputation-free survival, or mortality outcomes among patients who received OMM compared with non-OMM patients. CONCLUSIONS: Only a quarter of veterans with claudication were documented as receiving OMM within the year before undergoing open lower extremity bypass across nationwide VA medical centers, highlighting the need for strategies to ensure that medical therapy is intensified before surgical revascularization. Nevertheless, our data showed that documentation of preoperative OMM did not lead to improved short- or long-term postoperative outcomes in these patients, suggesting that more objective measures of medical management are needed to ensure that peripheral arterial disease goals are achieved.
引用
- Williams CR, Jellison A, Martin L, et al. Optimal medical management before lower extremity bypass for claudication in the veteran population. J Vasc Surg. 2018. PMID: 30108008. doi:10.1016/j.jvs.2018.05.222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。